The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors

Jonathan R. Strosberg*, Thorvardur R. Halfdanarson, Andrew M. Bellizzi, Jennifer A. Chan, Joseph S. Dillon, Anthony P. Heaney, Pamela L. Kunz, Thomas M. O'Dorisio, Riad Salem, Eva Segelov, James R. Howe, Rodney F. Pommier, Kari Brendtro, Mohammad A. Bashir, Simron Singh, Michael C. Soulen, Laura Tang, Jerome S. Zacks, James C. Yao, Emily K. Bergsland

*Corresponding author for this work

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.

Original languageEnglish (US)
Pages (from-to)707-714
Number of pages8
JournalPancreas
Volume46
Issue number6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Neuroendocrine Tumors
Guidelines
Carcinoid Tumor
Therapeutics
Small Intestine
Gastrointestinal Tract
Colon
Lung
Liver

Keywords

  • Medical management
  • Midgut NETs
  • NANETS
  • Neuroendocrine tumor

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., ... Bergsland, E. K. (2017). The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas, 46(6), 707-714. https://doi.org/10.1097/MPA.0000000000000850
Strosberg, Jonathan R. ; Halfdanarson, Thorvardur R. ; Bellizzi, Andrew M. ; Chan, Jennifer A. ; Dillon, Joseph S. ; Heaney, Anthony P. ; Kunz, Pamela L. ; O'Dorisio, Thomas M. ; Salem, Riad ; Segelov, Eva ; Howe, James R. ; Pommier, Rodney F. ; Brendtro, Kari ; Bashir, Mohammad A. ; Singh, Simron ; Soulen, Michael C. ; Tang, Laura ; Zacks, Jerome S. ; Yao, James C. ; Bergsland, Emily K. / The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. In: Pancreas. 2017 ; Vol. 46, No. 6. pp. 707-714.
@article{66d06a808eb94e5c81bdd99eb0742fd2,
title = "The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors",
abstract = "There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.",
keywords = "Medical management, Midgut NETs, NANETS, Neuroendocrine tumor",
author = "Strosberg, {Jonathan R.} and Halfdanarson, {Thorvardur R.} and Bellizzi, {Andrew M.} and Chan, {Jennifer A.} and Dillon, {Joseph S.} and Heaney, {Anthony P.} and Kunz, {Pamela L.} and O'Dorisio, {Thomas M.} and Riad Salem and Eva Segelov and Howe, {James R.} and Pommier, {Rodney F.} and Kari Brendtro and Bashir, {Mohammad A.} and Simron Singh and Soulen, {Michael C.} and Laura Tang and Zacks, {Jerome S.} and Yao, {James C.} and Bergsland, {Emily K.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MPA.0000000000000850",
language = "English (US)",
volume = "46",
pages = "707--714",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Strosberg, JR, Halfdanarson, TR, Bellizzi, AM, Chan, JA, Dillon, JS, Heaney, AP, Kunz, PL, O'Dorisio, TM, Salem, R, Segelov, E, Howe, JR, Pommier, RF, Brendtro, K, Bashir, MA, Singh, S, Soulen, MC, Tang, L, Zacks, JS, Yao, JC & Bergsland, EK 2017, 'The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors', Pancreas, vol. 46, no. 6, pp. 707-714. https://doi.org/10.1097/MPA.0000000000000850

The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. / Strosberg, Jonathan R.; Halfdanarson, Thorvardur R.; Bellizzi, Andrew M.; Chan, Jennifer A.; Dillon, Joseph S.; Heaney, Anthony P.; Kunz, Pamela L.; O'Dorisio, Thomas M.; Salem, Riad; Segelov, Eva; Howe, James R.; Pommier, Rodney F.; Brendtro, Kari; Bashir, Mohammad A.; Singh, Simron; Soulen, Michael C.; Tang, Laura; Zacks, Jerome S.; Yao, James C.; Bergsland, Emily K.

In: Pancreas, Vol. 46, No. 6, 01.01.2017, p. 707-714.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors

AU - Strosberg, Jonathan R.

AU - Halfdanarson, Thorvardur R.

AU - Bellizzi, Andrew M.

AU - Chan, Jennifer A.

AU - Dillon, Joseph S.

AU - Heaney, Anthony P.

AU - Kunz, Pamela L.

AU - O'Dorisio, Thomas M.

AU - Salem, Riad

AU - Segelov, Eva

AU - Howe, James R.

AU - Pommier, Rodney F.

AU - Brendtro, Kari

AU - Bashir, Mohammad A.

AU - Singh, Simron

AU - Soulen, Michael C.

AU - Tang, Laura

AU - Zacks, Jerome S.

AU - Yao, James C.

AU - Bergsland, Emily K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.

AB - There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.

KW - Medical management

KW - Midgut NETs

KW - NANETS

KW - Neuroendocrine tumor

UR - http://www.scopus.com/inward/record.url?scp=85020887054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020887054&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000850

DO - 10.1097/MPA.0000000000000850

M3 - Article

C2 - 28609356

AN - SCOPUS:85020887054

VL - 46

SP - 707

EP - 714

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 6

ER -